Trying to nip at AstraZeneca's heels, Lilly and Boehringer Ingelheim stop a PhIII Jardiance study early in kidney disease
Eli Lilly and Boehringer Ingelheim revealed Wednesday that a big part of their plans to compete with AstraZeneca’s Farxiga has been validated.
A Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
